To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.
case-control studies of the Ovarian Cancer Association Consortium (OCAC) and BRCA1 and BRCA2 mutation carriers of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). These data were combined with genotype data from the Collaborative Oncological Gene-environment Study (COGS) project 14, 19 and three EOC GWAS 8, 9 . We present the results of these association analyses together with functional annotation of the new genome-wide significant EOC susceptibility loci.
RESULTS

Association analyses
We performed genetic association analyses using genotype data from 25,509 population-based EOC cases and 40,941 controls from OCAC and meta-analysis of these data with 19,036 BRCA1 and 12,412 BRCA2 mutation carriers from CIMBA, of whom 2,933 and 954, respectively, were affected with EOC. The numbers of participants by study for OCAC and CIMBA are shown in Supplementary Tables 1 and 2, respectively.
We used data from the 1000 Genomes Project 20 reference panel to impute genotypes for 11,403,952 common variants (minor allele frequency (MAF) >1%) and evaluated the associations of these SNPs with EOC risk. In OCAC alone, nine histotypes were investigated (all invasive, serous invasive, HGSOC, LGSOC, serous borderline, LGSOC and serous borderline combined, ENOC, CCOC and MOC). Association analyses identified six new loci associated with serous EOC histotypes at genome-wide significance (P < 5 × 10 −8 ): rs9870207 at 3q28, rs13113999 at 4q32.3, rs150293538 at 8q21.11, rs7902587 at 10q24.33, rs8098244 at 18q11.2 and rs6005807 at 22q12.1. Five of these loci were associated with borderline serous EOC (3q28, 4q32.3, 8q21.11, 10q24.33 and 18q11.2), and four were associated with LGSOC tumors (3q28, 8q21.11, 10q24.33 and 18q11.2) ( Table 1) . We also identified two loci associated with MOC (rs112071820 at 3q22.3 and rs320203 at 9q31.1) and one locus associated with ENOC (rs555025179 at 5q12. EOC is a heterogeneous disease commonly classified into five major histotypes of invasive disease 1 (high-grade serous (HGSOC), lowgrade serous (LGSOC), mucinous (MOC), endometrioid (ENOC) and clear cell (CCOC) carcinoma) and two histotypes of borderline disease (serous and mucinous). The histotypes have differences in lifestyle and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and prognosis. HGSOC is thought to be derived from fallopian tube secretory epithelial cells through foci of endosalpingiosis existing as inclusion cysts lined with tubal epithelium at the ovarian and peritoneal surface 2 . In contrast, CCOC, ENOC and sero-endometrioid carcinomas appear to develop from endometriosis 3, 4 . MOC resembles adenocarcinoma of the gastric pylorus, intestine or endocervix, and the majority of these tumors show gastrointestinal differentiation 5 .
Approximately 20% of the familial component of EOC risk is attributable to high-to-intermediate risk genes 6 . An unknown fraction is due to more common, lower-risk genetic variation 7 . In European populations, genome-wide association studies (GWAS) have identified 23 EOC susceptibility alleles, including 18 common variants associated with all histologies and/or serous EOC [8] [9] [10] [11] [12] [13] [14] [15] , 1 associated with borderline serous tumors 13 , 3 associated with MOC 16 and 1 associated with CCOC 12 . The majority of these loci also showed associations (P < 0.05) with EOC risk for BRCA1 or BRCA2 mutation carriers 15 . Five additional loci associated with EOC and breast and/or prostate cancer have been identified 17 ; three of these were associated with susceptibility to EOC, breast cancer and prostate cancer, and two were associated only with breast cancer and EOC risk. However, the common genetic variants explain only 3.9% of the inherited component of EOC risk 15 , and additional susceptibility loci are likely to exist, particularly for the less common non-serous histotypes.
We designed a custom Illumina array, named the OncoArray, to identify new cancer susceptibility loci 18 . The OncoArray includes ~533,000 variants (of which 260,660 formed a GWAS backbone) and has been used to genotype over 500,000 samples, including EOC identified three additional serous EOC risk loci (rs2165109 at 2q13, rs9886651 at 8q24.21 and rs7953249 at 12q24.31). The 8q24.21 SNP rs9886651 is close to two SNPs previously associated with serous EOC (ref. 9 and A. Gjyshi, G.M.-F., J.P.T., N.T. Woods and K.L. et al., unpublished data). Multivariable analysis of OCAC data showed that this is a third independent associated variant in this region (unadjusted odds ratio (OR) = 1.07, OR adjusted for rs1400482 and rs13255292 = 1.07). Variant rs6005807 at 22q12.1 was previously reported to be associated with serous EOC below genome-wide significance 21 .
The association of the top SNP in each region with the nine EOC histotypes studied with EOC risk in BRCA1 and BRCA2 mutation carriers is shown in Figure 1 . Four SNPs (rs8098244 (18q11.2), rs2165109 (2q13), rs9886651 (8q24.21) and rs7953249 (12q24.31)) showed associations with EOC risk for BRCA1 mutation carriers, and one SNP (rs9886651 (8q24.21)) showed an association with risk for BRCA2 mutation carriers (P < 0.05).
Eighteen of the 23 previously published loci were associated with the same histotype at genome-wide significance (excluding the 5 pleiotropic loci published by Kar et al. 17 ; Supplementary Table 3) . Of these, 11 showed association with EOC risk for BRCA1 mutation carriers, and 8 showed association with risk for BRCA2 mutation carriers (P < 0.05). There was significant heterogeneity of risk between the five main, non-overlapping histotypes (high-grade serous, low-grade/borderline serous, endometrioid, clear cell and invasive/ borderline mucinous) for 28 of the 40 new and previously published loci (Supplementary Table 3) .
We carried out a competing-risks association analysis in BRCA1 and BRCA2 mutation carriers to investigate whether the observed associations with ovarian cancer in mutation carriers are influenced by associations with breast cancer risk. For this analysis, we used the most significantly associated genotyped SNPs 22 . The EOC hazard ratio (HR) estimates were consistent with the estimates from the main analysis for all SNPs (data not shown). Some evidence suggested that rs7953249 at 12q24.31 was associated with reduced breast cancer risk in BRCA1 mutation carriers (HR = 0.95, 95% confidence interval (CI) = 0.91-0.99, P = 0.034) and that SNP rs2165109 at 2q13 was associated with increased breast cancer risk in BRCA2 mutation carriers (HR = 1.08, 95% CI = 1.01-1.14, P = 0.02). When these associations were analyzed by tumor estrogen receptor (ER) status, the associations for the two SNPs were restricted to ER-negative breast cancer for BRCA1 (P = 0.026 for rs7953249) and BRCA2 (P = 0.02 for rs2165109) mutation carriers.
Association analyses adjusted for the most significant SNP in each region (including three independent SNPs at 8q24.21) did not identify any additional independent association signals in these regions. At the 12 new EOC risk regions, 571 SNPs were deemed potentially causal (Supplementary Table 4 ) and carried forward for functional annotation, expression quantitative trait locus (eQTL) and methylation quantitative trait locus (mQTL) analyses.
Functional and molecular analyses
Of the 571 candidate causal variants in the 12 newly identified loci, 562 variants are located in noncoding DNA sequences and may influence the expression of nearby target genes 23 . We used a variety of in silico approaches to identify putative, tissue-specific regulatory biofeatures and candidate susceptibility genes associated with risk SNPs at each locus. For the few risk-associated nonsynonymous variants in protein-coding genes, we also evaluated predicted effects on protein function.
Functional annotation of candidate causal alleles. We mapped the set of 562 non-protein-coding candidate causal SNPs at the 12 susceptibility loci to regulatory biofeatures, using a variety of epigenomic marks profiled in normal and cancer tissues relevant to the cellular origins of the different ovarian cancer histotypes (Supplementary Table 5 ). The cell types interrogated included (i) fallopian tube (FT33 and FT246) and ovarian surface (IOSE4 and IOSE11) epithelial cell lines for serous precursor tissues; (ii) serous-related cancer cell lines, including HGSOC cell lines (UWB1.289 and CaOV3) and a LGSOC cell line (OAW42); (iii) endometriosis epithelial cells (EEC16), as a likely precursor of ENOC; and (iv) cell types relevant to MOC, including MOC cell lines (GTFR230 and MCAS) and both colonic normal (colon crypt) and cancer (HCT116 and HeLa-S3) tissues. The epigenomic marks annotated were open chromatin, identified using formaldehyde-assisted isolation of regulatory element sequencing (FAIRE-seq) and DNase I hypersensitivity sequencing (DNase-seq), and chromatin immunoprecipitation sequencing (ChIP-seq) of histone modifications, specifically histone H3 lysine 27 acetylation (H3K27ac; denoting active chromatin) and histone H3 lysine 4 monomethylation (H3K4me1; marking active and poised enhancers). SNPs were also intersected with Encyclopedia of DNA Elements (ENCODE) transcription factor ChIP-seq data. All tissue types were evaluated for all risk loci. The SNP-biofeature intersections by tissue type are illustrated in Figure 2 and Supplementary Table 6 . A r t i c l e s Nine (1.6%) of the 571 candidate causal SNPs lie in protein-coding sequences. Five of these are synonymous and four are nonsynonymous but predicted to be benign by PolyPhen-2 (Supplementary Table 6 ). Four SNPs lie within the UTRs of protein-coding genes and so could affect mRNA stability: rs1051149 and rs1051150 in the 3′ UTR of LAMA3 and rs12327412 in the 5′ UTR of TTC39C, all at the 18q11.2 locus, and rs1018128 in the 3′ UTR of GMNC at 3q28. The majority of SNP-biofeature intersections (n = 166; 29% of all candidate causal SNPs and 97% of candidate causal SNPs overlapping a biofeature) were for SNPs lying within active chromatin and/or open chromatin. Eleven SNPs lie in the promoters of four genes (PVT1, HNF1A, TTC39C and TTC28) (Supplementary Table 6 ).
At six serous risk loci (4q32.3, 3q28, 8q21, 18q11, 8q24 and 22q12), we observed extensive SNP-biofeature overlaps, particularly in serous-related tissue types. In contrast, the two MOC susceptibility loci (3q22.3 and 9q31.1) were biofeature-poor regions and showed little or no SNP-biofeature intersection in any of the tissue types under investigation, including MOC and ENCODE cell lines. At the endometrioid EOC risk locus (5q12.3), we observed enhancers in endometriosis, ovarian, fallopian and EOC cell types flanking the small number of risk-associated SNPs (n = 8), none of which coincided with regulatory elements.
Several studies have shown that common variant susceptibility alleles are significantly enriched for regulatory elements detected in disease-relevant tissue types. Therefore, we tested for enrichment of SNP-H3K27ac intersections at each locus because H3K27ac was the most comprehensively profiled regulatory feature across different tissue types (Supplementary Table 7) . At the 12q24.31 locus, a large region of active chromatin spanning the HNF1A promoter drove a strong enrichment for risk SNP-H3K27ac intersection in the OAW42
LGSOC cell line (P = 4. A r t i c l e s binding in ovarian and ENCODE data sets, and these highly active regions showed extensive overlap with candidate causal alleles (Fig. 3) .
Identifying candidate susceptibility gene targets at risk loci. We used several approaches to identify candidate target genes at the 12 risk loci. First, we hypothesized that target genes underlying disease susceptibility are more likely to display prevalent copy number alterations in ovarian tumor tissues. Amplifications were the most frequent alteration at 6 of the 12 susceptibility loci ( Supplementary  Fig. 1 ). Contiguous genes were commonly amplified in the same sample, indicating segmental amplifications (data not shown). HNF1A, ORAI1, CHEK2, XPB1, BUB1 and FOXL2 are found inside the same topologically associating domain (TAD) as candidate causal SNPs and have been previously implicated in ovarian cancer development (Supplementary Fig. 2) . Notably, HNF1A, ORAI1 and FOXL2 are amplified in >5% of EOC samples. No TAD was identified for 8q24.21, but MYC and PVT1 appear to be the targets for multiple enhancer elements containing independent EOC risk associations for HGSOC at this locus (A. Gjyshi, G.M.-F., J.P.T., N.T. Woods and K.L. et al., unpublished data).
We also performed eQTL and mQTL analyses in several data sets comprising methylation/expression profiling and germline genotyping in relevant tumor tissues (Online Methods). For eQTL analyses, we evaluated associations between the candidate causal SNPs and all genes profiled within 1 Mb of the index risk SNP at each locus, as this window will contain most cis-eQTL associations 23 . Results of the eQTL analyses in each data set were adjusted for tumor copy number and methylation status 24 , and a meta-analysis of the two HGSOC data sets from The Cancer Genome Atlas (TCGA) and the Mayo Clinic are shown in Supplementary Tables 8-11 . The most significant eQTL associations in both HGSOC data sets were identified between the candidate causal risk SNPs at the 10q24.33 risk locus and OBFC1 expression (TCGA rs11597399, P = 3.1 × 10 −10 ; Mayo rs7902587, P = 4.0 × 10 −4 ; meta-analysis rs34379047, P = 2.1 × 10 −11 ). The risk (T) allele was associated with reduced OBFC1 expression in both data sets (Fig. 3d) . We then evaluated all SNPs at this locus (not just the candidate causal SNPs) for eQTL associations; the SNPs with the most significant eQTL associations for OBFC1 were also candidate causal SNPs for the risk association, reinforcing OBFC1 as the likely target gene. No expression associations were identified at P < 1 × 10 −4 for the candidate causal risk SNPs at any other locus in the eQTL metaanalysis. We used 32 ENOC samples to conduct an eQTL analysis focused on the 5q13.1 ENOC risk locus, but this did not identify any associations at P < 0.05 (Supplementary Table 10 ).
mQTL analyses were restricted to the set of 67 CpGs with the most significant association with decreased expression of the 74 genes of interest (within a 1-Mb region centered on the index SNP) in the 12 regions. Results are presented for the most significant mQTL associations for each SNP based on the reduced set of CpGs (Supplementary Table 12 ). We identified two regions with mQTL associations at P < 0.005. At 2q13, the risk allele (G) of rs56226558 was associated with reduced methylation of the CpG cg21469370 (P = 1.4 × 10 −3 ), with methylation being associated with reduced expression of BCL211 (P = 1.1 × 10 −6 ), even though cg21469370 lies in the gene body of ACOXL. At 3q22.3, the risk allele (C) of rs68088905 was associated with reduced methylation of the CpG cg06726820 in the promoter of RBP1 (mQTL P = 4.9 × 10 −3 ). Methylation was A r t i c l e s strongly associated with reduced RBP1 expression (P = 1.7 × 10 −36 ). We found no highly significant mQTL associations for genes at any other locus, and the eQTL SNP at 10q24.33 was not associated with DNA methylation. SNPs in the 10q24.33 locus showed the most significant eQTL effects on expression of the OBFC1 gene. The most significant eQTL SNPs also showed the most epigenetic marks, including rs35007589 (eQTL P = 2.3 × 10 −11 ), rs35176048 (eQTL P = 2.6 × 10 −11 ) and rs34685262 (eQTL P = 3.8 × 10 −11 ). These SNPs intersect regions of open chromatin, H3K27ac and H3K4me1 signal in normal ovarian and fallopian tube epithelial cells and, for rs35176048 and rs34685262, in HGSOC cell lines. These enhancers are not specific to ovarian cell types. At this locus, 11 candidate causal SNPs are predicted by motifbreakR 25 to alter transcription factor binding sites, of which 8 are predicted to have a strong effect on transcription factor binding (Supplementary Table 13 ). Of particular interest, rs2488000 (eQTL P = 1.4 × 10 −10 ) is predicted in silico to strongly influence the binding of CTCF, a ubiquitously expressed transcriptional regulator that has a key role in insulator function and chromatin structure (Fig. 3c) . Furthermore, in ENCODE, there is evidence from ChIP-seq experiments that CTCF does bind at this location in monocytes. Other SNPs predicted to have a strong effect on the binding of other cancer-relevant transcription factors are rs11813268 (ETS1), rs7907606 (FOXP1) and rs2995264 (IRF8) (Supplementary Table 13) .
At 8q24.21, the candidate causal variants span a ~20-kb region that includes the promoter and first exon of PVT1, an oncogenic long noncoding RNA (lncRNA) with known roles in breast and ovarian cancers 26 . The 8q24 region is also a hotspot for association with other cancers 27 , with PVT1, MYC and novel lncRNAs identified as candidate target genes. Five SNPs (rs10956390, rs10098831, rs6470578, rs6990534 and rs4410871) coincide with 11 or more biofeatures in normal ovarian and fallopian tube epithelial cells and in ovarian cancer cells.
DISCUSSION
We have identified 12 new loci associated with different histotypes of EOC at genome-wide significance. Despite the use of a stringent significance threshold, it is possible that some of these represent false positive associations. Wakefield has suggested the use of an approximate Bayes factor to calculate the Bayes false discovery probability (BFDP) 28 . We have estimated the BFDP on the basis of a plausible odds ratio of 1.2 and a prior probability of association of 0.0001. The BFDP was less than 10% for 11 of the 12 associations. We also calculated the BFDP values for the 22 previously reported loci, of which 17 were <1%, 1 was >1% but less than 10%, and 4 were greater than 10%. We did not calculate the BFDP for the five pleiotropic loci reported by Kar et al. 17 . These 5 loci, together with the 29 loci with BFDP <10%, bring the total number of susceptibility loci for different histotypes of EOC to 34 for women of European ancestry, of which 27 are associated with risk of invasive EOC at P < 0.01. Assuming a polygenic variance of 1.45 (ref. 29) , the 27 loci account for approximately 6.4% of the polygenic risk in the population. Incorporating common EOC susceptibility variants into risk assessment tools will improve risk prediction and may be particularly useful for refining risk estimates in BRCA1 and BRCA2 mutation carriers.
Some strata in the OCAC analyses pooled data from several studies from the same country. This might increase the potential for bias because of population stratification, but we expect any inflation due to population stratification to be effectively removed by adjusting for the principal components. To evaluate the possible magnitude of such a bias, we compared the inflation of the median test statistic for the analysis of the OncoArray data stratified by study with that for an analysis in which all the cases and controls were combined into a single stratum. There was little difference (λ = 1.054 versus λ = 1.078). As these inflation factors are not adjusted for sample size, some of the difference is due to the higher effective sample size of the non-stratified analysis, suggesting that any bias due to pooling data from multiple studies will be minimal.
Consistent with previous studies in EOC and other cancer types, the vast majority of the risk-associated variants were located in nonprotein-coding regions of the genome 30 , suggesting that these variants influence target gene expression by altering the activity of functional element(s) that regulate the expression of one or more susceptibility genes. Because noncoding biofeatures, such as enhancers, show a high degree of tissue specificity, we intersected EOC risk SNPs with regions of active chromatin catalogued in cell lines representing the different EOC histotypes (HGSOC, ENOC, LGSOC and MOC) and in EOC precursor cells (OSEC/FTSEC for LGSOC/HGSOC, EEC for ENOC and colonic crypt for MOC). Enrichment analyses test for over-representation of cell-type-specific biofeatures intersecting risk variants at confirmed risk loci, in comparison to a lack of enrichment in non-disease-associated tissues. A major strength of our approach was the ability to interrogate histotype-specific epigenomic profiles, and so, in addition to identifying the putative functional targets of risk SNPs, these analyses can also indicate whether some cell types are more likely to be relevant to disease pathogenesis than other cell types. For example, we detected a significant enrichment of active chromatin marks coinciding with SNPs in fallopian tube epithelial cells at the 10q24. 33 LGSOC/borderline serous locus, which could reflect recent pathological evidence that some of these tumors arise in the distal fallopian tube 31 , as well as HGSOC 2 . At the same locus, we also identified enrichment for biofeatures in a primary MOC cell line, a cancer histotype that is often associated with deregulation of the MAPK pathway, which is also perturbed in LGSOC 32 . Given the growing evidence that regulatory mechanisms are highly tissue specific, it is perhaps to be expected that we find such enrichments in cell types associated with EOC development. However, the lack of enrichment at MOC and ENOC risk loci may indicate that alternative precursor cell types give rise to these histotypes rather than the cell types evaluated in the current study. eQTL analysis identified associations between the most statistically significant risk-associated SNPs at 10q24.33 and OBFC1, many of which also coincide with epigenetic biofeatures. OBFC1 is a subunit of an alpha accessory factor that stimulates the activity of DNA polymerase α primase, the enzyme that initiates DNA replication. OBFC1 also appears to function in a telomere-associated complex that binds telomeric single-stranded DNA in vitro and localizes at telomeres in vivo 33 . Four SNPs in this region (rs2487999, rs4387287, rs9420907 and rs9419958) have previously been reported to be associated with telomere length (NHGRI-EBI GWAS catalog 27 ; Supplementary Table 14) . The r 2 values between these and rs7902587 are between 0.52 and 0.93 (1000 Genomes Project European populations). However, the associations of all four with LGSOC and borderline serous EOC are attenuated when adjusted for rs7902587, suggesting a single association peak. The alleles associated with an increase in leukocyte telomere length are associated with increased risk of LGSOC and borderline serous EOC. These findings are consistent with the association between borderline EOC and rs7705526 at 5p15 (adjacent to the telomerase reverse transcriptase gene TERT) 13 . Furthermore, the histotype specificity is consistent with the suggestion that telomere length differs between the different histotypes of EOC 34 .
Candidate causal variants at 3 of the 12 new loci are associated with multiple traits in the NHGRI-EBI GWAS catalog (P < 5 × 10 −8 ).
These traits converge on pathways involved in inflammation and immunity, including monocyte count, C-reactive protein (CRP) levels, γ-glutamyl transpeptidase levels, N-glycan levels, allergen sensitization and multiple sclerosis (Supplementary Table 14) . For example, at the 12q24.31 HGSOC risk locus, the risk alleles of four candidate causal SNPs (rs7979473, rs1183910, rs2393791 and rs7310409) have previously been associated with elevated CRP levels in blood plasma, a marker of inflammation. This is consistent with the established link between chronic inflammation and increased cancer risk. In addition, SNPs within 500 kb of the top SNP at 2q13, 8q24.21, 10q24.33 and 22q12.1 are associated with several different cancers, although only one of these is a candidate causal EOC variant (rs2995264 at 10q24.33 associated with cutaneous malignant melanoma).
This study demonstrates the strength of large-scale collaborations in identifying common variant risk associations for complex traits such as EOC, which is rare, has a high mortality rate and exhibits heterogeneity by histotype. As the largest study thus far with over 90,000 EOC cases and controls, including an additional ~25,000 previously unstudied participants, we identify several new risk loci specific to rarer EOC histotypes: ENOC, MOC, LGSOC and borderline EOC. The histotype-specific nature of these associations adds to the somatic, epidemiological and clinical data indicating that EOC histotypes can be thought of as distinct diseases. The lack of heterogeneity between studies of varying designs, carried out in different populations, and the high levels of statistical significance, with confirmation of known EOC susceptibility loci, provide evidence that these are robust associations. Molecular analyses of genes and the tissue-specific regulatory architecture at these loci, which combined publicly available data sets with systematic, large-scale genome-wide profiling experiments, point to a small number of noncoding biofeatures and target genes that may have a histotype-specific role in EOC initiation and development. Detailed functional studies will be required to define the underlying biology of SNP-regulatory feature interactions to identify the causal SNP(s) at each locus, and to confirm which candidate susceptibility genes represent the targets of these risk SNPs. Evolving technologies, in particular CRISPR-Cas9 genome editing, now enable precise modification of risk SNPs to create isogenic models of different alleles 35 
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AUtHoR contRIBUtIons
ONLINE METhODS
Study samples. Genotype data from six OCAC and two CIMBA genotyping projects were used for these analyses (Supplementary Table 1 ). All participating studies were approved by the relevant research ethics committee, and all participants provided written, informed consent.
OCAC. The OCAC OncoArray data comprised 63 genotyping project/casecontrol sets (Supplementary Table 1 ). Some studies (for example, SEARCH) contributed samples to more than one genotyping project, and some casecontrol sets are a combination of multiple individual studies. The following numbers are for the subjects of European ancestry that passed quality control. The analyses included 66,450 samples from seven genotyping projects: 40,941 controls, 22,406 invasive cases and 3,103 borderline cases. The number of cases by histotype was as follows: serous borderline (1,954), mucinous borderline (1,149), LGSOC (1,012), HGSOC (13,037), ENOC (2,810), CCOC (1, 366) and other EOC (2, 764) .
CIMBA. Eligibility in CIMBA is restricted to females aged 18 years or older with pathogenic variants in BRCA1 or BRCA2. The majority of the participants were sampled through cancer genetics clinics, including some related participants. Sixty-three studies contributed OncoArray and iCOGS genotype data on 31,448 mutation carriers. For the samples genotyped on the OncoArray, after quality control, data were available on 15,694 BRCA1 mutation carriers and 10,988 BRCA2 mutation carriers, of whom 2,372 and 849, respectively, were affected with EOC (Supplementary Table 2 ). We also obtained genotype data on 3,342 (561 affected) BRCA1 and 1,424 (105 affected) BRCA2 nonoverlapping samples genotyped using the iCOGS array 19, 39 .
Genotype data and quality control. Data from all the genotyping projects apart from the OCAC and CIMBA OncoArray projects have been published previously 8, 9, 14, 15, 19 . Genotypes for OCAC samples were preferentially selected from the different projects in the following order: OncoArray, Mayo GWAS, COGS and other GWAS. Genotyping was performed at five centers: University of Cambridge, Center for Inherited Disease Research (CIDR), National Cancer Institute (NCI), Génome Québec and Mayo Clinic (Supplementary Table 15 ). OncoArray sample quality control was similar to that carried out for the other projects (as described in ref. 14) . We excluded samples if they had a genotyping call rate <95%, if they had excessively low or high heterozygosity, if they were not female or if they were duplicates (cryptic or intended). Duplicates and close relatives were identified using in-house software that calculates a concordance matrix for all individuals. Samples with concordance >0.86 were flagged as duplicates, and samples with concordance between 0.74 and 0.86 were flagged as relatives. The comparison was performed among all the OncoArray samples and among all the previously genotyped samples. The concordance statistics were used to identify cryptic duplicates and expected duplicates whose genotypes did not match. We attempted to resolve these with the study investigators. If the discrepancy could not be resolved, both samples were excluded. In OCAC, for confirmed cryptic duplicates and relatives, we retained one sample in the analysis. For case-control pairs, we excluded the control, while for case-case and control-control pairs we excluded the sample with the lower call rate. In CIMBA, relatives were included in the analysis and the association tests were adjusted accordingly. For confirmed duplicates, the sample with the higher call rate was retained. SNP quality control was carried out according to the OncoArray QC Guidelines 18 . Only SNPs that passed quality control for all consortia were used for imputation. We excluded SNPs with a call rate <95%, SNPs deviating from Hardy-Weinberg equilibrium (P < 1 × 10 −7 in controls or unrelated samples in CIMBA and P < 1 × 10 −12 in cases) and SNPs with concordance <98% among 5,280 duplicate pairs. For imputation, we additionally excluded SNPs with MAF <1% and call rate <98%, SNPs that could not be linked to the 1000 Genomes Project reference or differed significantly in frequency from the 1000 Genomes Project (European frequency) and a further 1,128 SNPs where the cluster plot was judged to be inadequate. Of the 533,631 SNPs that were manufactured on the array, 494,813 SNPs passed the initial quality control and 470,825 SNPs were used for imputation. Samples with overall heterozygosity <5% or >40% were excluded. Ancestry analysis. Intercontinental ancestry was calculated for the OCAC samples using the software package FastPop (http://sourceforge.net/projects/ fastpop/) 40 developed specifically for the OncoArray. Only samples with >80% European ancestry were used for these analyses. For the CIMBA samples, 33,661 weakly correlated autosomal SNPs (pairwise r 2 < 0.1) were used to compute the genomic kinship between all pairs of individuals, along with 267 HapMap samples (CHB, JPT, YRI and CEU). These were converted to distances and subjected to multidimensional scaling. Using the first two components, we calculated the proportion of European ancestry for each individual and excluded samples with >27% non-European ancestry to ensure that samples of Ashkenazi Jewish ancestry were included in the final sample. Analysis using FastPop provided virtually identical results.
Principal-component analysis. Principal-component analysis for the OncoArray data was carried out using data from 33,661 uncorrelated SNPs (pairwise r 2 < 0.1) with MAF >0.05 using an in-house program (available at http://ccge.medschl.cam.ac.uk/software/pccalc/). Principal-component analysis for the other genotype data sets was carried out as previously described 14, 19 .
Imputation. We performed imputation separately for each genotyping project data set. We imputed genotypes into the reference panel from the 1000 Genomes Project (v3 October 2014) 20 . We initially used an efficient two-step procedure, which involved prephasing using SHAPEIT 41 followed by imputation of the phased data using IMPUTE2 (ref. 42) . We then performed more accurate imputation for any region with a SNP with P < 1 × 10 −6 in the OCAC analyses or the OCAC and CIMBA meta-analysis. The boundaries were set ±500 kb from the most significant SNP in each region. The singlestep imputation used IMPUTE2 without prephasing with some of the default parameters modified. These included an increase of the MCMC iterations to 90 (of which the first 15 were used as burn-in), an increase of the buffer region to 500 kb and an increase to 100 of the number of haplotypes used as templates when phasing observed genotypes.
After imputation, 85% of common variants, including both single-nucleotide variants and small indels (MAF > 0.05), had imputation r 2 imputation accuracy >0.9, with 97% having imputation r 2 >0.7. Of the rare variants (0.001 < MAF < 0.05), 28% had imputation r 2 >0.9 and 58% had imputation r 2 >0.7.
Association analyses in the unselected ovarian cancer cases and controls from OCAC and CIMBA. We excluded SNPs from the association analysis if their r 2 imputation accuracy was <0.3 or MAF was <0.01. In total, genotypes for 11,595,112 million variants were available for analysis.
Association analyses in OCAC.
We evaluated the association between genotype and disease using the imputed genotype dosage in a logistic regression model. We carried out initial genome-wide analyses separately for OncoArray, COGS and the five GWAS data sets and pooled the results using a fixedeffects meta-analysis. The analyses were adjusted for study and for population substructure by including the eigenvectors of project-specific principal components as covariates in the model (nine for OncoArray, five for COGS, two for UK GWAS, two for the US, BWH and POL GWAS, and a single principal component for the MAY GWAS). The number of eigenvectors chosen was based on the inflection point of a scree plot. After one-step imputation of the genotypes in the regions of interest, we used genotype dosages in a single logistic regression model with adjustment for each genotyping project/study combination and 19 principal components. Principal components were set to zero for samples not included in a given project. We used custom written software for the analysis.
EOC is a heterogeneous phenotype with five major histotypes for invasive disease (HGSOC, LGSOC, MOC, ENOC and CCOC) and two histotypes of borderline disease (serous and mucinous). The pattern of association across the different histotypes varies for the known EOC risk loci. We therefore carried out the association analysis on the following nine histotypes: all invasive disease; HGSOC; LGSOC; all invasive serous; serous borderline; LGSOC and borderline serous combined; ENOC; CCOC; and mucinous invasive/mucinous borderline combined.
Association analyses in CIMBA. We carried out the ovarian cancer association analyses separately for BRCA1 and BRCA2 mutation carriers and for OncoArray and COGS samples. The results were pooled using fixed-effects to the same depth as the larger data set. To control the irreproducible discovery rate (IDR) in ChIP-seq analysis, we used the IDR version 2.0 pipeline 49 . A standard IDR threshold of P < 0.05 was applied.
Functional annotation of variants. We used shell scripts with BEDtools (http://bedtools.readthedocs.org/en/latest/) to generate overlap data between all variants in each associated region including likely causal SNPs and BED file versions of all the data represented in Figure 2 and Supplementary  Table 6 . In addition, we included 3′ UTRs, 5′ UTRs, miRcode high-confidence conserved microRNA target sites, high-confidence microRNA target sites from http://microRNA.org/ and all coding exons. The overlap data thus obtained were converted to matrix form by means of Python scripts. MicroRNA target sites were only considered if they overlapped UTR gene regions. Exonic variants were further assessed for missense or nonsense mutations by MuTect software 50 . The NHGRI-EBI GWAS catalog was used to identify SNPs among the potentially causal set with other genome-wide significant associations (Supplementary Table 14) .
Locus-specific tissue enrichment of variants. H3K27 acetylation peaks were collated from public sources (for HeLa-S3, HCT116, UCSD ovary, UCSD sigmoid colon and colon crypt) or from in-house data (IOSE4, IOSE11, FT33, FT246, EEC16, CaOV3, UWB1.289, OAW42, GFTR230 and MCAS) (Supplementary Tables 5 and 16 ). Overlaps were counted for all SNPs against which genotypes were imputed in the 1000 Genomes Project for each H3K27ac data set. The fraction of causal SNPs with overlaps was then tested for significance against this background for each cell type in the H3K27ac data sets using the hypergeometric distribution. Finally, P values were adjusted for multiple comparisons using Bonferroni's method.
Data availability. OncoArray germline genotype data for the OCAC studies have been deposited at the European Genome-phenome Archive (EGA; https:// ega-archive.org/), which is hosted by the EBI and the CRG, under accession EGAS00001002305. Summary results are available from the Ovarian Cancer Association Consortium (http://ocac.ccge.medschl.cam.ac.uk/). A subset of the OncoArray germline genotype data for the CIMBA studies will be made publically available through the database of Genotypes and Phenotypes (dbGaP) under accession phs001321.v1.p1. The complete data set will not be made publically available because of restraints imposed by the ethics committees of individual studies; requests for further data can be made to the Data Access Coordination Committee (http://cimba.ccge.medschl.cam.ac.uk/). ChIP-seq data are available from the Gene Expression Omnibus (GEO; http:// www.ncbi.nlm.nih.gov/geo/) under accession GSE68104.
